In medical institutions, antigen test kits are usually used to diagnose whether a person has COVID-19 or influenza virus infection. In hospitals, the increase in waiting time for medical treatment and the unstable supply of antigen test kits have become issues for medical practice because many patients visit hospitals in a short period of time during the epidemic season.

Continued technological development through the development of new antigen test kits

The Company has been researching and developing antigen test kits for more than 20 years. We are striving to shorten the time required to judge test results and improve operability by leveraging our accumulated experience and know-how.
As a concrete initiative, we are studying the optimal combination of antibodies used in antigen test kits to shorten the evaluation time. Also, in order to improve operability, we are working to enhance visibility and the layout of the judgment lines so that the results can be seen at a glance.
We are always asking ourselves what makes our products easy to use and reliable for medical professionals, and are studying every day to achieve our target in product performance and quality.

Eliminating the shortage of test kits by establishing a stable supply system

In order to ensure stable delivery of antigen test kits in the quantity required for medical treatment in the event of a sudden outbreak, the Company not only manufactures antigen test kits at its own facility, but also has established a system to enable mass production in a short period of time in cooperation with partner companies.

Expected Benefits

The Company’s efforts will further improve the speediness and operability of antigen test kits, enabling stable delivery of products to medical facilities. As a result, a large number of patients can be treated smoothly in a shorter time at the medical site, reducing the burden on both medical staff and patients. It also gives patients peace of mind that they can obtain a diagnosis quickly.

Future Developments

We will strive to maintain and improve our production system and continue to address the social issue of supplying safe, reliable, and high-quality test drugs. We will also set up a system that enables us to quickly develop and launch test drugs when a new infectious disease emerges.